Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer.

@article{Gualberto2009DevelopmentOT,
  title={Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer.},
  author={Antonio Gualberto and Daniel D Karp},
  journal={Clinical lung cancer},
  year={2009},
  volume={10 4},
  pages={
          273-80
        }
}
Figitumumab (CP-751,871) is a fully human immunoglobulin G2 monoclonal antibody highly potent and specific against the insulin-like growth factor-1 receptor. Figitumumab has an effective half-life of approximately 20 days, and it has been well tolerated in clinical studies when given alone or in combination with chemotherapy and targeted agents. Mild to moderate asymptomatic hyperglycemia is observed with figitumumab therapy, but it is generally manageable and well tolerated. Because of its… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2010
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Molecular diagnosis in lung diseases.

VIEW 1 EXCERPT
CITES BACKGROUND

Lack of any prognostic role of insulin-like growth factor-1 receptor in non-small cell lung cancer.

  • Asian Pacific journal of cancer prevention : APJCP
  • 2014
VIEW 1 EXCERPT
CITES BACKGROUND